Sangel Capital
Asia, Guangdong, China, Shenzhen'/%3e%3cuse xlink:href='%23a' transform='rotate(23.036 .093 25.536)'/%3e%3cuse xlink:href='%23a' transform='rotate(45.87 1.273 16.18)'/%3e%3cuse xlink:href='%23a' transform='rotate(69.945 .996 12.078)'/%3e%3cuse xlink:href='%23a' transform='rotate(20.66 -19.689 31.932)'/%3e%3c/svg%3e)
Description
one of the earliest globally operating professional biomedical venture capital institutions in China
Investor Profile
Sangel Capital has backed more than 6 startups, with 0 new investments in the last 12 months alone. The firm has led 0 rounds, about 0% of its total and boasts 3 exits across its portfolio.
Investment Focus Highlights
- Concentrates on Series B, Series C, Series A rounds (top funding stages).
- Majority of deals are located in United States, Canada.
- Strong thematic focus on Biotechnology, Health Care, Pharmaceutical.
Stage Focus
- Series B (50%)
- Series C (33%)
- Series A (17%)
Country Focus
- United States (83%)
- Canada (17%)
Industry Focus
- Biotechnology
- Health Care
- Pharmaceutical
- Biopharma
- Medical
- Medical Device
- Genetics
- Therapeutics
FAQ
Frequently Asked Questions
Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.
